Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study

by biblioteca on 22 de gener de 2024 with No hi ha comentaris

Janjigian, Y. Y., Al-Batran, S. E., Wainberg, Z. A., Van Cutsem, E., Molena, D., Muro, K., . . . Tabernero, J. (2023). Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study. Annals of Oncology, 34, S1315-S1316. https://doi.org/10.1016/j.annonc.2023.10.074